Verismo Therapeutics Celebrates Third Year as a Best Place to Work in Philadelphia

Verismo Therapeutics: A Leading Workplace in Philadelphia

In a remarkable achievement, Verismo Therapeutics has once again secured its position in the spotlight by earning a spot on the Philadelphia Business Journal's 2025 Best Places to Work list. This marks the third consecutive year that the clinical-stage CAR T company, which is focused on pioneering KIR-CAR technology, has been honored with this accolade. The recognition highlights the company's unwavering dedication to cultivating a positive work environment, fostering employee engagement, and promoting a culture of excellence.

The annual award is based on extensive feedback from employees, evaluated through confidential surveys that assess their work experiences, job satisfaction, and the overall workplace culture. Verismo’s ongoing commitment to attracting top talent and maintaining high employee morale is evident in this recognition, which reflects true employee sentiment and corporate culture.

Bryan Kim, the CEO and co-founder of Verismo Therapeutics, expressed his pride in the achievement, stating, “Being recognized for the third year in a row is a reflection of the team-first culture we've worked to cultivate. We're proud to have created an environment where people are driven by purpose and supported in following their passion to help patients.” This statement underscores the company's ethos of putting its workforce first, understanding that satisfied employees are pivotal in delivering enhanced healthcare solutions.

About Verismo Therapeutics

Verismo Therapeutics, part of HLB Innovation, is at the forefront of CAR T therapy development, specifically with its innovative KIR-CAR technology. The company currently has two assets, SynKIR™-110 and SynKIR™-310, advancing through Phase 1 clinical trials. Notably, Verismo is distinguished as the only entity dedicated to developing the KIR-CAR platform, which employs a modified receptor derived from natural killer (NK) cells combined with DAP12 for enhanced T cell performance. This technology aims to improve T cell functional persistence while reducing exhaustion, ultimately resulting in greater efficacy in targeting challenging tumors.

The KIR-CAR platform stands out for its ability to address significant unmet medical needs within the oncology landscape, specifically targeting advanced solid tumors and B-cell malignancies. Early preclinical trials have demonstrated its potential by showcasing resilient responses against tumors that typically resist conventional CAR T therapies. This innovative approach not only offers hope for improved cancer treatments but also illustrates Verismo’s commitment to transforming the landscape of cancer therapies.

The Impact of Workplace Culture in Healthcare

Creating a workplace that prioritizes employee satisfaction is particularly vital in high-stakes industries like healthcare and biotechnology. At Verismo, fostering a supportive environment promotes not just employee retention but also drives the motivation needed to innovate and discover new therapeutic solutions. The company’s culture thrives on mutual respect, collaboration, and shared objectives, all of which are essential in the fast-evolving field of biotech.

Ultimately, Verismo Therapeutics' continuous recognition as one of the Best Places to Work underscores the significance of a positive workplace culture in enhancing productivity and innovation. By nurturing a team-oriented atmosphere, the company is well-positioned to propel breakthroughs in cancer treatment, making substantial strides toward improving patient outcomes while operating at the cutting edge of scientific advancement.

For more information about Verismo Therapeutics and their impactful KIR-CAR technology, visit www.verismotherapeutics.com.